Latest Boardroom Shifts News

Big moves came from disclosure drama, CEO change news, and one standout software upgrade. While several stocks jumped on results, a few gaps couldn’t hold as traders sold into early strength.

Touch Ventures Limited reported a $4.6 million net loss for 2025, driven by investment impairments and foreign exchange impacts, while appointing Gannet Capital as its new investment manager to revamp its portfolio strategy.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

Regal Asian Investments Limited (ASX, RG8) has updated its Dividend Reinvestment Plan, eliminating the minimum participation requirement and streamlining administrative processes for shareholders.

Alkane Resources Ltd has reported a remarkable half-year surge in revenue and profit, driven by its strategic merger with Mandalay Resources Corporation and soaring gold prices.

PeopleIN Limited has appointed co-founder Tom Reardon as its new CEO and Managing Director, signaling continuity in leadership as the company reports a robust unaudited EBITDA of $16.1 million.

Minbos Resources has appointed Rob Newbold as Acting CEO following the resignation of Lindsay Reed, while grappling with administrative and shareholder challenges delaying its key phosphate project in Angola.

Dusk Group Limited has reported a solid 5.2% increase in net profit for the half year ended December 2025, alongside a 5.1% rise in revenue. The company also announced a fully franked interim dividend doubling the prior payout, signalling confidence in its retail operations.

GQG Partners Inc. reported a 6.3% increase in net revenue and a 7.3% rise in net profit for 2025, alongside a strategic US ETF launch and a new dividend declaration.

Podium Minerals has disclosed the initial securities interests of its newly appointed directors, highlighting a significant allocation of performance rights to Gary Humphries while Neal Froneman holds none.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Elixinol Wellness reported a 9.5% revenue increase in Q4 FY25 alongside a 30% reduction in operating costs, setting a clear path to profitability under fresh executive leadership.